|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.345 HKD | -4.17% |
|
+4.55% | -44.35% |
| Apr. 12 | Clover Biopharmaceuticals, Ltd. announced that it has received $0.320713 million in funding | CI |
| Apr. 08 | Clover Biopharmaceuticals' RSV Vaccine Candidate Shows Promise in Early Trial | MT |
Clover Biopharmaceuticals, Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was CNY 39.26 million. Net loss was CNY 138.54 million compared to CNY 2,451.9 million a year ago.
Basic loss per share from continuing operations was CNY 0.11 compared to CNY 2.22 a year ago. Diluted loss per share from continuing operations was CNY 0.11 compared to CNY 2.22 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -44.35% | 59.65M | |
| -2.39% | 103B | |
| +1.87% | 95.28B | |
| +1.69% | 22.15B | |
| -15.30% | 21.02B | |
| -8.58% | 18.15B | |
| -41.01% | 16.73B | |
| -13.12% | 16.05B | |
| +4.20% | 13.68B | |
| +35.72% | 12.17B |
CLOVER BIOPHARMACEUTICALS, LTD. 
